FDA clears Healis Therapeutics’ IND for Tyemvers®, Enabling U.S. Neuropsychiatric TrialsCAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Healis Therapeutics announced that it has opened an IND with the U.S. FDA for Tyemvers®, a new botulinum toxin type A product. The milestone enables Healis to initiate its U.S. clinical trial, enter clinical-stage research and development, and advance toward participation in the therapeutic botulinum toxin market.
Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South KoreaNEWPORT BEACH, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, is thrilled to share that strategic partner, Chong Kun Dang Bio (063160:Korea SE), has released topline results from Phase III on Healis’ lead compound, CKDB-501A.
Healis selected to present at key biotechnology and neuroscience investor conferences in Amsterdam, New York, and San DiegoNEWPORT BEACH, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics is pleased to announce it has been competitively selected to present at several key investor conferences.
Healis Therapeutics Announces Supply Agreement with CKD Bio to develop CKDB-501 for neuropsychiatric indicationsNEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation (A063160.KS) for CKDB-501, a neuromodulator BoNT/A protein. CKD Bio is a subsidiary of Chong Kun Dang group based in Seoul, South Korea.
Healis Therapeutics selected to speak on opening day of 2024 Biotech Showcase in San FranciscoNEWPORT BEACH, Calif. and BROOKLYN, N.Y., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Healis Therapeutics is pleased to announce that it has been competitively selected to present at the Biotech Showcase taking place January 8-10, 2024 in San Francisco. The conference is being held in parallel to the J.P. Morgan 42nd Annual Healthcare Conference.
